Regeneron Pharmaceuticals (REGN) Change in Acquisitions & Divestments (2009 - 2026)

Regeneron Pharmaceuticals' Change in Acquisitions & Divestments history runs 18 years deep, the most recent figure standing at $2.1 billion for Q2 2026.

• In Q2 2026, Change in Acquisitions & Divestments fell 0.89% year-over-year to $2.1 billion; the TTM figure through Jun 2026 stood at $10.7 billion (down 14.37% YoY), while the FY2025 annual figure was $11.5 billion, down 23.17% from the prior year.
• Change in Acquisitions & Divestments for Q2 2026 stood at $2.1 billion, down from $2.6 billion in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $4.3 billion in Q3 2024, with the low at $746.3 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $2.5 billion (2023), against an average of $2.6 billion.
• The sharpest annual moves came in 2022 and 2025: Change in Acquisitions & Divestments soared 383.46% in 2022, then tumbled 46.53% in 2025.
• Regeneron Pharmaceuticals' Change in Acquisitions & Divestments stood at $1.5 billion in 2022, then jumped by 55.0% to $2.4 billion in 2023, then climbed by 8.36% to $2.6 billion in 2024, then slipped by 1.05% to $2.6 billion in 2025, then decreased by 15.91% to $2.1 billion in 2026.
• Business Quant data shows REGN's Change in Acquisitions & Divestments at $2.1 billion in Q2 2026, $2.6 billion in Q1 2026, and $2.6 billion in Q4 2025.